Skip to main content

Table 1 Longitudinal cohort baseline characteristics

From: The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease

  Controls MCI Alzheimer’s
disease
p-valuec
All MCI-MCI MCI-AD
N 57 54 27 27 27
Sex (% f/m) 65/35 53/47 44/56 59/41 52/48 - d
Age at examination (yrs)a 68 ± 5 65 ± 6 66 ± 6 64 ± 4 64 ± 6 ** e
MMSEb 30 (28–30) 28 (23–30) 28 (25–30) 27 (23–29) 23 (16–27) *** f
APOEε4 carrier (%) 38 (n = 55) 66 63 74 81 *** d
CSF 969.7 546.5 574.3 539.0 476.8 *** f
1–42 (500–1674) (173–1269) (173–1269) (283–1060) (212–1092)
(pg/mL)b (n = 45)
CSF 17.1 13.5 12.9 14.2 14.9 ** f
1–40 (11–41) (4–31) (4–31) (8–23) (7–29)
(ng/mL) b (n = 41) (n = 26) (n = 23) (n = 26)
CSF 0.059 0.042 0.049 0.039 0.034 *** f
42/40 b (0.013–0.096) (0.008–0.118) (0.008–0.118) (0.012–0.088) (0.007–0.080)
(n = 41) (n = 26) (n = 23) (n = 26)
CSF 269.0 447.9 315.2 550.8 624.2 *** f
t-tau (138–1314) (99–2325) (99–1057) (163–2325) (177–1540)
(pg/mL)b (n = 46)
CSF 53.5 69.9 53.0 85.6 90.8 *** f
p-tau (33–135) (16–169) (16–131) (37–169) (28–157)
(pg/mL)b (n = 46)
  1. MCI = mild cognitive impairment MCI-MCI = MCI patients who remained MCI at the 24-month follow up
  2. MCI-AD = MCI patients who converted to Alzheimer’s disease at the 24-month follow up
  3. MMSE = Mini-Mental State Examination score
  4. a = mean ± standard deviation b = median (minimum-maximum)
  5. c = P-value reflecting potential differences between the groups Controls, mild cognitive impairment and Alzheimer’s disease d = χ2 test e = one-way ANOVA f = Kruskal-Wallis test - = non-significant
  6. ** = p ≤ 0.01 *** = p ≤ 0.001